Onconetix (ONCO) has released an update.
Ajit Singh has been appointed to the Board of Directors of a company after the resignation of Neil Campbell. Dr. Singh, with a deep background in technology and life science investments, is a Partner at Artiman Ventures, boasting over $1 billion in assets under management. He holds a wealth of experience, serving on various boards in the healthcare sector, teaching at Stanford’s School of Medicine, and holding a remarkable track record in the industry, including a successful tenure as President and CEO of Biolmagene, acquired by Roche Pharmaceuticals. His extensive expertise is complemented by a strong academic foundation, with a Ph.D. in Computer Science and multiple published works.
For further insights into ONCO stock, check out TipRanks’ Stock Analysis page.
